Application for conditional marketing authorisation of melflufen (melphalan flufenamide) for multiple myeloma submitted to the European Medicines Agency

Melflufen is a peptide-drug conjugate that targets aminopeptidases (overexpressed in multiple myeloma cells; associated with advanced disease) and rapidly releases alkylating agents inside cancer cells. The application is based on data from the phase 2 HORIZON study.

Source:

Biospace Inc.